1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33075
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSpelman, Tim-
dc.contributor.authorOzakbas, Serkan-
dc.contributor.authorAlroughani, Raed-
dc.contributor.authorTerzi, Murat-
dc.contributor.authorHodgkinson, Suzanne-
dc.contributor.authorLaureys, Guy-
dc.contributor.authorKalincik, Tomas-
dc.contributor.authorDer Walt, Anneke Van-
dc.contributor.authorYamout, Bassem-
dc.contributor.authorLechner-Scott, Jeannette-
dc.contributor.authorSoysal, Aysun-
dc.contributor.authorKuhle, Jens-
dc.contributor.authorSanchez-Menoyo, Jose Luis-
dc.contributor.authorMorgado, Yolanda Blanco-
dc.contributor.authorSpitaleri, Daniele LA-
dc.contributor.authorPesch, Vincent van-
dc.contributor.authorHorakova, Dana-
dc.contributor.authorAmpapa, Radek-
dc.contributor.authorPatti, Francesco-
dc.contributor.authorMacdonell, Richard A L-
dc.contributor.authorAl-Asmi, Abdullah-
dc.contributor.authorGerlach, Oliver-
dc.contributor.authorOh, Jiwon-
dc.contributor.authorAltintas, Ayse-
dc.contributor.authorTundia, Namita-
dc.contributor.authorWong, Schiffon L-
dc.contributor.authorButzkueven, Helmut-
dc.date2023-
dc.date.accessioned2023-06-16T06:48:40Z-
dc.date.available2023-06-16T06:48:40Z-
dc.date.issued2023-08-
dc.identifier.citationNeurodegenerative Disease Management 2023; 13(4)en_US
dc.identifier.issn1758-2032-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33075-
dc.description.abstractPatient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments. Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS. The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.en_US
dc.language.isoeng-
dc.subjectcladribine tabletsen_US
dc.subjectdimethyl fumarate (Tecfidera®)en_US
dc.subjectfingolimod (Gilenya®)en_US
dc.subjectlay summaryen_US
dc.subjectmultiple sclerosisen_US
dc.subjectrelapsesen_US
dc.subjectteriflunomide (Aubagio®)en_US
dc.subjecttreatment optionsen_US
dc.titleA plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleNeurodegenerative Disease Managementen_US
dc.identifier.affiliationMSBase Foundation, Melbourne, Australia.en_US
dc.identifier.affiliationDokuz Eylul University, Izmir, Turkey.en_US
dc.identifier.affiliationAmiri Hospital, Sharq, Kuwait.en_US
dc.identifier.affiliationDepartment of Neurology 19 Mayis University, Samsun, Turkey.en_US
dc.identifier.affiliationLiverpool Hospital, Sydney, Australia.en_US
dc.identifier.affiliationUniversity Hospital Ghent, Ghent, Belgium.en_US
dc.identifier.affiliationMS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australiaen_US
dc.identifier.affiliationDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.en_US
dc.identifier.affiliationNeurology Institute, Harley Street Medical Center, Abu Dhabi, United Arab Emiratesen_US
dc.identifier.affiliationSchool of Medicine & Public Health, University of Newcastle, Newcastle, Australiaen_US
dc.identifier.affiliationBakirkoy Education & Research Hospital for Psychiatric & Neurological Diseases, Istanbul, Turkey.en_US
dc.identifier.affiliationMultiple Sclerosis Centre, Neurology, Departments of Head, Spine & Neuromedicine, Biomedicine & Clinical Research, University Hospital Basel & University of Basel, Basel, Switzerlanden_US
dc.identifier.affiliationDepartment of Neurology, Galdakao-Usansolo University Hospital, Osakidetza-Basque Health Service, Biocruces-Bizkaia Health Research Institute, Galdakao, Spain.en_US
dc.identifier.affiliationCenter of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain.en_US
dc.identifier.affiliationAzienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy.en_US
dc.identifier.affiliationCliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.en_US
dc.identifier.affiliationDepartment of Neurology & Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague & General University Hospital, Prague, Czech Republic.en_US
dc.identifier.affiliationNemocnice Jihlava, Jihlava, Czech Republic.en_US
dc.identifier.affiliationDepartment of Medical & Surgical Sciences & Advanced Technologies, GF Ingrassia, Catania, Italy.en_US
dc.identifier.affiliationNeurologyen_US
dc.identifier.affiliationNeurology Unit, Department of Medicine, College of Medicine & Health Sciences & Sultan Qaboos University Hospital, SQU, Al Khodh, Oman.en_US
dc.identifier.affiliationAcademic MS Center Zuyderland, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlandsen_US
dc.identifier.affiliationDivision of Neurology, St Michael's Hospital, University of Toronto, Toronto, Canada.en_US
dc.identifier.affiliationKoc University School of Medicine & Koc University Research Center for Translational Medicine (KUTTAM) Istanbul, Turkey.en_US
dc.identifier.affiliationEMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.en_US
dc.identifier.affiliationDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.en_US
dc.identifier.affiliationCORe, Department of Medicine, University of Melbourne, Melbourne, Australia.en_US
dc.identifier.affiliationAmerican University of Beirut Medical Center, Beirut, Lebanon.en_US
dc.identifier.affiliationDepartment of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, Australia.en_US
dc.identifier.affiliationResearch Center for Clinical Neuroimmunology & Neuroscience (RC2NB), University Hospital & University of Basel, Switzerland.en_US
dc.identifier.affiliationSchool for Mental Health & Neuroscience, Maastricht University, Maastricht, The Netherlands.en_US
dc.identifier.doi10.2217/nmt-2023-0005en_US
dc.type.contentTexten_US
dc.identifier.pubmedid37287269-
local.name.researcherMacdonell, Richard A L
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

44
checked on Nov 24, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.